crestor 40 mg
orifarm as - rosuvastatinkalsium - tablett, filmdrasjert - 40 mg
crestor 20 mg
orifarm as - rosuvastatinkalsium - tablett, filmdrasjert - 20 mg
zenon 40 mg / 10 mg
paranova as - rosuvastatinkalsium / ezetimib - tablett, filmdrasjert - 40 mg / 10 mg
zenon 10 mg / 10 mg
orifarm as - rosuvastatinkalsium / ezetimib - tablett, filmdrasjert - 10 mg / 10 mg
zenon 20 mg / 10 mg
orifarm as - rosuvastatinkalsium / ezetimib - tablett, filmdrasjert - 20 mg / 10 mg
zenon 40 mg / 10 mg
orifarm as - rosuvastatinkalsium / ezetimib - tablett, filmdrasjert - 40 mg / 10 mg
dronedaron aristo 400 mg
aristo pharma gmbh - dronedaronhydroklorid - tablett, filmdrasjert - 400 mg
kaletra
abbvie deutschland gmbh co. kg - lopinavir, ritonavir - hiv-infeksjoner - antivirals for systemic use, protease inhibitors - kaletra er angitt i kombinasjon med andre antiretrovirale legemidler til behandling av hiv-1-infiserte voksne, ungdommer og barn i alderen 14 og eldre. valg av kaletra til å behandle protease inhibitor opplevd hiv-1 infiserte pasienter bør være basert på individuelle viral motstand testing og behandling historie av pasienter.
orserdu
stemline therapeutics b.v. - elacestrant - bryst neoplasms - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - karsinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.